

1 **An *in silico* integrative analysis of hepatocellular carcinoma omics databases shows the**  
2 **dual regulatory role of microRNAs either as tumor suppressors or as oncomirs**

3 **Mahmoud M. Tolba<sup>1,2</sup> , Bangli Soliman<sup>2, 3</sup>, Abdul Jabbar<sup>4</sup>, HebaT'Allah Nasser<sup>5</sup>,**  
4 **Mahmoud Elhefnaw<sup>2, 3</sup>**

5 <sup>1</sup>Pharmaceutical Division, Ministry of Health and Population, Faiyum, Egypt

6  
7 <sup>2</sup> Informatics and Systems Department, Division of Engineering research, National Research  
8 centre, Cairo 12622, Egypt

9 <sup>3</sup>Biomedical Informatics and Chemoinformatics Group, Centre of Excellence for medical  
10 research, National Research Centre, Cairo 12622, Egypt

11 <sup>4</sup> Department of Clinical Medicine, Faculty of Veterinary Science, University of Veterinary and  
12 Animal Sciences, 54600, Lahore Punjab Pakistan

13 <sup>5</sup> Microbiology and Public Health Department, Faculty of Pharmacy and Drug Technology,  
14 Heliopolis University, Cairo, Egypt

15 Corresponding author: **Mahmoud M. Tolba**

16 Email: mahmoud.tolba109@gmail.com

17  
18 **Abstract:**

19 MicroRNAs are well known as short RNAs bases, 22 nucleotides, binding directly to  
20 3'untranslated region (3'UTR) of the messenger RNA to repress their functions. Recently,  
21 microRNAs have been widely used as a therapeutic approach for various types of Cancer.  
22 MicroRNA is categorized into tumor suppressor and oncomirs. Tumor suppressor microRNAs  
23 can repress the pathologically causative oncogenes of the hallmarks of Cancer. However, based  
24 on the fact that miRNA has no proper fidelity to bind specific mRNAs due to binding to off-  
25 targets, it results in a kind of inverse biological activity. Here, we have executed an *in-silico*  
26 integrative analysis of GEO/TCGA-LIHC of genes/microRNAs expression analysis in HCC,  
27 including (446 HCC vs. 146 normal specimens for miRNAs expression ) ad 488 specimens for  
28 genes expression. It virtually shows that microRNAs could have an ability to target both  
29 oncogenes and tumor suppressor genes that contribute to its dual activity role as a tumor

30 suppressor and oncomirs via miRNA-lncRNA-TFs-PPI Crosstalk. Seven resultant microRNAs  
31 show a putative dual role in HCC. It enhances our concluded suggestion of using combination  
32 therapy of tumor suppressor genes activators with microRNAs.

33 **Keywords:** *in silico* tools; hepatocellular carcinoma; microRNAs

## 34 **1. Introduction**

35 Different types of Cancer are the lead diseases where the scientific community hunts for new  
36 approaches to cure them. One of these approaches is epigenetic therapy [1]. Epigenetics is a  
37 genetic field that strengthens our knowledge to comprehensively understand the factors that  
38 control the genes translations within the cells [2]. Long non-coding RNAs, small interfering  
39 RNA, and microRNAs are among these factors that control the translation of the genes [3-5].  
40 This activity controls various biological processes such as cellular differentiation, cell signaling,  
41 life span, and apoptosis. Cancer is a disease of deregulation of the normal state of biological  
42 processes called cancer hallmarks [6].

43 Here we are focusing on Hepatocellular carcinoma (HCC), which is promptly considered one  
44 of the most prevalent cancers worldwide [7-9]. With a rising rate, it is a prominent source of  
45 mortality. Patients with advanced fibrosis, predominantly cirrhosis, and hepatitis B are  
46 predisposed to developing HCC. Individuals with chronic hepatitis B and C infections are most  
47 commonly suffering [10]. Different therapeutic options, including liver resection,  
48 transplantation, systemic and local therapy, must be tailored to each patient [11]. One of the most  
49 promising therapies for HCC is microRNAs therapy. It is well demonstrated that tens of  
50 microRNAs have an ectopic expression in HCC. It directly correlates with the cancerous  
51 pathway by inducing the list of oncogenes list with the cancerous cells. The therapeutic approach  
52 by the restoration of microRNAs is inclined to suppress the oncogenes, decreasing Cancer [12].

### 53 **1.1 miRNAs**

54 MicroRNA dates back to the year 1993 as the first time the microRNAs term has been  
55 enlightening. The first microRNA ever was c.elegan let 7. It regulates the c.elegan timing  
56 development [13].

57 MicroRNAs are classes of non-coding RNAs that play an important role in gene expression  
58 regulation in Cancer [14, 15]. They are generally transcribed from DNA sequences into primary  
59 miRNA and processed into precursor miRNAs, and finally mature miRNAs [3]. The principal  
60 role of microRNAs is to control protein translation by binding to complementary sequences in  
61 the 3' untranslated region (UTR) of target messenger RNAs (mRNAs) and thus deleteriously  
62 regulate mRNA translation. The microRNA–mRNA binding site is short (6–8 base pairs), and  
63 then each microRNA has the prospective to target multiple different mRNAs [16, 17].

## 64 **1.2 MicroRNA Biogenesis**


65 MicroRNAs biosynthesis has been well studied. The more well-known biogenesis pathway is  
66 the canonical pathway by which microRNAs are processed [18]. The canonical biogenesis  
67 pathway can be described as follows: pri-microRNAs are transcribed from their genes. This  
68 process into pri-miRNAs by microprocessor complex (RNA Binding protein DiGeorge  
69 Syndrome Critical Region 8 (DGCR8) and a ribonuclease III enzyme, Drosha. DGCR8  
70 recognizes an N6-methyladenylated GGAC and other motifs within the pri-miRNA, while  
71 Drosha cleaves the pri-miRNA duplex at the base of the characteristic hairpin structure of pri-  
72 miRNA. Accordingly, two nt 3' overhang on pre-miRNA is formed, one pre-miRNAs are  
73 formed. They will be exported by exportin 5 (XPO5)/RanGTP complex and then processed by  
74 the RNase III endonuclease Dicer. This processing includes terminal loop removal, and  
75 consequently, immature miRNAs duplex is formed.

76 miRNA strand directionality determines the name of the mature form of miRNA. The 5p strand  
77 arises from the 5-end from pre-miRNA hairpin, while the 3p strand originates from the 3-end .  
78 The strands mentioned above were derived from the mature miRNA duplex, which can be loaded  
79 into the Argonaute (AGO) family of proteins (AGO1-4 in humans) in an ATP-dependent  
80 manner. For any given miRNA, this is a great difference between the proportional of AGO-  
81 loaded 5p or 3p, which depends on the cell type or cellular environment. They may occur as one  
82 more predominant than the other. The 5p or 3p strand selection is based on the thermodynamic  
83 stability at the 5' ends of the miRNA duplex or a 5' U at nucleotide position1. Commonly, the  
84 lower 5-strand or 5-uracil strand is likely loaded into AGO and estimated the guide strand. The  
85 unloaded strand (passenger strand) is the unwanted strand from the guide strand through various  
86 mechanisms depending on the complementarity degree. The microRNA passenger strand with no

87 mismatches is AGO2 sliced and cellular machinery degraded. Therefore, strong bias can be  
88 produced. On the other hand, central mismatches miRNA duplexes or non-AGO2 loaded miRNA  
89 are inertly unwound and degraded [19-21].

### 90 **1.3 Bioinformatics role in cancer therapy:**

91 Through Bioinformatics analysis of microarray and high through genomic data, hundreds of  
92 ectopic expression of genes and microRNAs within various cancer types have been discovered  
93 via free online Bioinformatics tools that play an effective role in predicting new targets for  
94 microRNA and its genetic enrichment [22]. There are many free online tools [23] that show the  
95 binding mode of tens of predicted genes for each microRNA, such as RNA22 [24], DIANA [25],  
96 and miRanda [26]. It helps most in discovering new targets for the miRNAs for wet-lab  
97 experiments. Here, multiple genes/microRNAs expression datasets have been used to uncover  
98 the interaction of miRNAs with mRNAs, long non-coding RNA (LncRNA) [27], transcription  
99 factors (TFs) [28], and protein-protein interaction (PPI) [29]. For miRNA-mRNA-LncRNA-TFs-  
100 PPI crosstalk analysis, the followed work pipeline has helped most in putatively visualize all the  
101 factors that may have a control on miRNAs path to be biologically active as oncomiR or tumor  
102 suppressor as shown in the following flowchart (Figure 1).



103  
104 Figure 1: Flowchart of the implemented workflow illustrates the methods that have been  
105 followed.

106 A pool of the most differentially expressed miRs in HCC has been evolved and showed for their  
107 involved actions in tumor development or progression. Interestingly in this context, our current  
108 study will aim to perform a bioinformatics protocol on a huge list of the significantly down  
109 expressed microRNAs within the HCC cells to unveil their activity role. It was found that one  
110 microRNA has a potential role in working as a tumor suppressor and tumor activator for the  
111 hallmarks of liver cancer.

## 112 2. Methodology

### 113 2.1 Collecting data of the significantly down-expressed microRNAs in HCC:

114 Using NCBI Pubmed <https://www.ncbi.nlm.nih.gov/pubmed/>, we have searched for all  
115 published scientific articles and reviews working on microRNAs as a therapeutic approach for

116 liver cancer. We used "MicroRNA+Hepatocellular Carcinoma" as a query for our search. To  
117 deepen our data, we utilized the PhenomiR [30] database to get all the microRNAs related to  
118 Hepatocellular carcinoma.

119 To enrich our work, we have surveyed different registry of NCBI Gene Expression Omnibus  
120 microarray databases for the miRs, and interestingly we have chosen five databases [31, 32] and  
121 one TCGA LIHV –RNA seq databases with broad samples of 446 HCC vs. 146 adjacent normal  
122 specimens which cover cirrhosis and G2/M phase of HCC.

123 These six integrated datasets are "Miltenyi Biotec miRXplore miRNA Microarray, GSE28854",  
124 Capital Bio Mammalian miRNA Array Services V1 [1].0, GSE10694", "Affymetrix Multispecies  
125 miRNA-2 Array, GSE74618"Affymetrix Multispecies miRNA-4 Array, GSE115016" "Agilent-  
126 031181 Unrestricted\_Human\_miRNA\_V16.0\_Microarray, GSE110217" and "TCGA-LIHC,  
127 RNA seq". These integrated datasets have been downloaded and analyzed by the Subio Platform  
128 PC program <http://www.subio.jp/products/platform> to be filtered to get the overlap of common  
129 down-expressed microRNAs in HCC specimens. The resultant list of the down-expressed  
130 miRNAs, from datasets analysis, has been cross–confirmed by the previously mentioned manual  
131 search within NCBI Pubmed and PhenomiR [33] .

## 132 **2.2 Collecting data of over-expressed genes in HCC:**

133 We have downloaded three integrated and recent datasets like miR datasets collection by  
134 utilizing NCBI GEO microarray databases. They included the following " Affymetrix Human  
135 Genome U133A 2.0 Array" GSE14520", "Affymetrix HT Human Genome U133A Array,  
136 GSE14520" and TCGA- LIHC, and they have been conducted by subio platform program to get  
137 the overexpressed genes in HCC.

## 138 **2.3 miRNAs-targets prediction**

139 First, an online miRBase database [34, 35] was used to get access to microRNAs. After that,  
140 we have utilized miRWalk [36] to get the predicted and validated target genes of each  
141 microRNA. Five different bioinformatics tools have been chosen to get the highest accuracy and  
142 specificity for our predicted genes data. These five tools were miRANDA [26], DIANA [25],  
143 RNAhybrid [37], targetscan [38] and RNA22 [24]. The validated miRNA targets by miRWalk

144 have been further enriched and confirmed via online experimental miRs-targets interaction  
145 databases such as DIANA-TarBase v7.0 [39] and mirtarbase databases [40].

## 146 **2.4 Enrichment and gene ontology**

147 David functional annotation [41] was run to get biological processes and genes ontology of  
148 each list of miRNA targets, which resulted from miRwalk. P-value < 0.05 was set as cut off of  
149 the chosen biological process. The common resultant genes from datasets analysis by subio  
150 platform and shown by miRwalk are enriched by David functional annotation.

151 The final step was data-filtration to highlight the biological process that is only related to  
152 hepatocellular carcinoma hallmarks to show the impact of microRNAs as either tumor  
153 suppressor or oncomiR. The previously filtrated genes have been used to draw a microRNAs-  
154 targets network by Cytoscape [42] to show the transcriptomic level's miRs interactions.

## 155 **2.5 miRNA-lncRNA interaction**

156 miRNet online tool [43] was used to determine the regulatory interaction of microRNA-  
157 LncRNA and microRNA-TFs interaction.

## 158 **2.6 miRNA-miRNA interaction**

159 TFmiR online tool [44] was used to get the regulatory roles of microRNA-microRNA  
160 interaction. TFmiR is based on disease-specific microRNAs of putative miRNA-miRNA  
161 regulations, PmmR database [45].

## 162 **2.7 miRNA- "Protein-Protein" interaction**

163 Differential gene expression (UP/down) has been used for PPI constructing network by  
164 STRING v10 tool [46]. The Biological processes of the resultant network were filtrated into the  
165 ones related to HCC. The genes incorporated in the output, Biological processes, were  
166 reanalyzed via miRWalk to get down expressed miRNAs in HCC, correlated to these BPs.


## 167 **2.8 Free survival analysis**

168 Here, the aim is to visualize the potential impact of microRNA on the HCC survival  
169 progression using GEPIA [47]. The selected genes on the central role of PPI by owning the  
170 highest number of edges.

### 171 3. Results

#### 172 3.1. MicroRNAs ectopic expression in HCC.

173 A list of 24 significantly down expressed microRNAs in HCC has been identified by Subio  
174 platform PC for the overall six datasets, including GEO and TCGA-LIHC, RNA seq databases  
175 (Figure 2). These down expressed microRNAs have been selected because they are common  
176 among at least two datasets out of the six datasets. They have been further confirmed via the  
177 PhenoMiR database (HCC).



178 Figure2: the down-expressed microRNAs in HCC, 24 microRNAs.


#### 180 3.2. Expression of genes targeted by the microRNAs

181 As one of the main criteria for microRNA is that it is used as a gene therapy, the targeted  
182 genes should be overexpressed within the HCC cell line. The overexpression of these genes  
183 alters its function to be cancerous genes via inducing cancerous biological processes. Here, GEO  
184 datasets and TCGA-LIHC database have been analyzed by subio platform to show the common  
185 up-expressed genes in all datasets, combined to HCC target genes which have previously shown  
186 by Disease-annotation of miRwalk for Hepatocellular carcinoma. It resulted in 180



187 overexpressed shared within," Affymetrix Human Genome U133A 2.0 Array" ' GSE14520",  
188 "Affymetrix HT Human Genome U133A Array, GSE14520" and TCGA- LIHC (Figure 3 a & b).  
189 Any gene, shown as down-expressed in HCC, has been excluded.

190



191


192 Figure 3: a) the differentially up-expressed genes in HCC

193

194

195

196




197

198 Figure 3: b) 180 genes are found to be common over-expression genes in HCC.

### 199 3.3. microRNAs-genes interactions.

200 Each microRNA of our 24 ones has hundreds of target genes resulted from an integrative  
201 analysis of HCC gene expression datasets by subplatform (Figure 2), combined with resultant  
202 genes from miRwalk related to HCC hallmarks, Disease-annotation of miRwalk for  
203 Hepatocellular carcinoma has been implemented for search, as combinatorial targets  
204 (supplementary 1). This analysis has evolved a list of HCC genes, further directed to determining  
205 the expected Cytoscape networking with our 24 mirs. Interestingly, the regulatory network of 24  
206 mirs with its target genes has been overviewed in (figure 4).




207


208 Figure4: A regulatory network of microRNAs, Red triangle, with their targets, drawn by  
209 Cytoscape.

### 210 **3.4. Biological Process of microRNAs.**


211 It was unveiled that microRNA has a biological process related to tumor suppressor and tumor  
212 activator (Figure 5).




213




214




215  
216




217  
218



219  
220



221  
222



223  
224 Figure5: BP of target genes of down expressed miRs in HCC. Green bars show the tumor  
225 suppressor activity of miRs. Red bars show their oncogenic activity.


226 Here, figure 4 shows a set of down-expressed microRNAs in HCC with their biological  
227 process of the genes targeted by microRNA; only the BP of  $P$ -value  $< 0.05$  has been selected.  
228 The dual role of microRNA in HCC is evaluated by the impact of microRNA on BP of HCC  
229 hallmarks either as an inducer or suppressor. The resultant is that each microRNA shows a dual  
230 role, either tumor suppressor (green bars) or onco-miR (red bars).

### 231 3.5. miRNA-TFs regulatory role

232 Four microRNAs have been found with abundant TFs targets (Figure 6).

233

234



235  
236 The figure 6: miRNA-TFs regulatory role.

237

238 Four microRNAs show tumor suppressor activity upon targeting TFs as transcriptional  
239 regulatory factors as ant-apoptosis and proliferation regulation. Hence, repressing these TFs  
240 results in tumor suppression, as shown in (table 1).


241 **Table 1:** shows Regulatory role of miRNA-TF interaction in HCC

MiRNA	TFs	Regulatory role of miRNA-TFs interaction in HCC
hsa-let-7c	AR,ESR1,EZH2,FOXO3,HOXA10,KHSR P,LIN28B,MYC,PRDM1,TRIM32	Tumor suppressor
hsa-mir-139	EZH2,JUN,REST,TP53	Tumor suppressor
hsa-mir-215	CDX1,TGFB1,TP53	Tumor suppressor
hsa-mir-223	CEBPB,DPF2,E2F1,HEY1,NFIA,NOTCH 1,NOTCH3 ,PRDM1,RELA,RUNX1,RUNX1T1,SPI1, TAL1,TWIST1	Tumor suppressor



243 **3.6. miRNA-LncRNA interaction**

244 Eight microRNAs have shown potential interaction with lncRNAs (Figure 7) ( Table 2).  
 245 LncRNA acts as a CeRNA sponge for microRNA. Subsequently, it results in the excessive  
 246 inhibitory activity of miRNA-mRNA interaction by excessive down-expressing of miRNAs.



247  
 248 Figure 7: miRNA-lncRNA regulatory role.

249 **Table 2:** shows Regulatory role of Therapeutic effect of microRNA-lncRNA on HCC

microRNA	LncRNA	Therapeutic effect of microRNA-lncRNA on HCC.
hsa-let-7c	AC074117.10,AC105760.2,CASP8AP2,CDKN2B-AS1,CTA-204B4.6,CTD-2270L9.5,CTD-3138B18.5,HOXA11-AS,KCNQ1OT1,LINC00263,LINC00665,MIR4720,NEAT1,NUTM2	Onco-miR

A-AS1,PTCHD3P1,RP11-1103G16.1,RP11-197N18.2,RP11-214O1.2,RP11-264B17.3,RP11-277P12.20,RP11-27I1.2,RP11-282O18.6,RP11-452L6.5,RP11-457M11.2,RP11-473I1.10,RP11-492E3.1,RP11-498P14.3,RP11-727A23.5,RP11-819C21.1,RP11-834C11.4,RP11-923I11.1,RP11-996F15.2,RP13,507I23.1,SCARNA10,TTY15,UBXN8,XIST,XXba  
c-BPG300A18.13,ZNF518A

hsa-mir-122-5p	AC005154.5, AC084ASB16-AS1,CDKN2B-AS1,CTA-204B4.6,CTC-503J8.6,CTD-2517M14.5, MAL2,MIR3179-1,MIR3179-2,PCBP1-AS1,RP11-290F20.1,RP11-518L10.2,RP11-571M6.18,RP6-24A23.7,SNHG7,VP S11	Onco-miR
hsa-mir-130a-3p	AC007038.7,AC007040.7,AC084018.1,AC084219.4,AC135048.13,AP001065.15,BOLA3-AS1,CCAT1,CTA-204B4.6,CTB-92J24.2,CTC-281B15.1,CTD-2369P2.2,CTD-3092A11.2,FGD5-AS1,H19,HOTAIR,HOXA11-AS,HOXD-AS1,KCNQ1OT1,LINC00116,LINC00339,LINC00667,LINC00839,MAP3K14,MIR17HG,NUTM2A-AS1,PRKCQ-AS1,RP11-197P3.5,RP11-290D2.4,RP11-344B2.2,RP11-355O1.11,RP11-361F15.2,RP11-363E7.4,RP11-429J17.6,RP11-588K22.2,RP11-656D10.3,RP11-73M18.8,RP1-178F10.3,RP11-84C13.1,RP13-638C3.2,RP4-639F20.3,SEC22B,SLC26A4-AS1,TMEM161B-AS1,XIST,ZNRD1-AS1	Onco-miR
hsa-mir-145-5p	AC016683.6,AC069513.3,AC142401.2,AL589743.1,C17orf76-AS1,CTA-204B4.6,CTD-2116N17.1,CTD-2516F10.2,GS1-251I9.4,HNRNPU-AS1,hsa-mir-132,IQCH-AS1,JPX,KCNQ1OT1,LINC00707,LINC00852,MAL2,MALAT1,MAPKAPK5-AS1,RP11-115D19.1,RP11-156E6.1,RP11-214C8.5,RP11-344E13.3,RP11-478C19.2,RP11-705C15.3,RP11-74E22.3,RP11-793H13.8,RP1-37E16.12,SCARNA10,SNHG1,TUG1,UHRF1	Onco-miR
hsa-mir-195-5p	AC003092.1,AC003104.1,AC004383.4,AC005154.5,AC005154.6,AC005537.2,AC005562.1,AC011893.3,AC016629.8,AC074093.1,AC084219.4,AC090587.2,AC091878.1,AC108142.1,AC113189.5,AP000721.4,AP001065.2,C14orf169,C1RL-AS1,CERS6-AS1,CTA-204B4.6,CTB-50E14.6,CTB-89H12.4,CTBP1-AS1,CTC-228N24.3,CTC-246B18.8,CTC-429P9.3,CTC-444N24.11,CTD-2201E18.3,CTD-2339L15.3,CTD-2516F10.2,CTD-2574D22.4,CWC15,DCP1A,DLG1-AS1,DLX6-AS1,EPB41L4A-AS1,ERI3-IT1,ERVK13-1,FENDRR,FGD5-AS1,GS1-124K5.11,GS1-358P8.4,HCG17,HCG18,IQCH-AS1,KIF9-AS1,LA16c306E5.2,LINC00094,LINC00176,LINC00339,LINC00473,LINC00511,LINC00649,LINC00662,LINC00707,LL22NC03-N27C7.1,MCM3AP-AS1,MEG8,MIR497HG,NUTM2A-AS1,PDXDC2P,PVT1,RASAL2-AS1,RP11-1103G16.1,RP11-	Onco-miR

---

hsa-mir-223	125K10.4,RP11-155D18.12,RP11-159D12.9,RP11-169K16.9,RP11-16E12.2,RP11-18A3.4,RP11-204M4.2,RP11-216F19.2,RP11-218M22.1,RP11-21N3.1,RP11-244H3.1,RP11-244O19.1,RP11-277L2.2,RP11-27I1.2,RP11-282K24.3,RP11-2C24.4,RP11-329L6.1,RP11-361F15.2,RP11-379K17.11,RP11-383C5.4,RP11-383J24.5,RP11-384K6.6,RP11-38J22.6,RP11-390P2.4,RP11-403I13.4,RP11-43D2.6,RP11-453E17.1,RP11-461L13.3,RP11-464F9.1,RP11-467L20.9,RP11-474P12.5,RP11-477D19.2,RP11-506M13.3,RP11-540O11.1,RP11-543D5.2,RP11-549J18.1,RP11-54O7.1,RP11-588K22.2,RP11-60I3.5,RP11-64K12.2,RP11-66B24.4,RP11-677M14.3,RP11-690G19.3,RP11-697M17.1,RP11-773D16.1,RP11-869B15.1,RP11-91G21.2,RP11-923I11.1,RP11-96D1.10,RP11-973H7.2,RP11-983P16.4,RP1-283E3.8,RP1-310O13.12,RP13-507I23.1,RP3-341D10.4,RP3-486L4.3,RP4-614O4.11,RP4-773N10.5,RP5-1028K7.2,RP5-1148A21.3,RP5-1172N10.3,RP5-1180C10.2,RP5-955M13.3,RP6-206I17.2,RP6-24A23.7,SCGB1B2P,SEMA3B,SENP3-EIF4A1,SLC37A4,SNHG1,SNHG12,SNHG16,SPPL2B,TRAF3IP2-AS1,TTN-AS1,XIST,XXbac-B461K10.4,XXbac-BPG32J3.20,ZNF518A,ZNRD1-AS1,AC006262.5 AC006262.5,AP001172.2,C17orf76-AS1,CTB-89H12.4,CTC-444N24.11,CTC-479C5.10,FGD5-AS1,GAS5,HOXA11-AS,INTS6-AS1,LINC00846,MAGI2-AS3,MIR155HG,MIR17HG,OIP5-AS1,PITPNA-AS1,POLDIP2,RP11-284N8.3,RP11-403I13.8	Onco-miR
hsa-mir-29c-3p	AC005154.5,AC005154.6,AC007036.5,AC012146.7,AP000304.2,CTD-2116N17.1,CTD-2339L15.1,CTD-2517M14.5,EMG1,GAS5,GS1-124K5.11,H19,HCP5,HOXA-AS3,HOXA-AS4,KCNQ1OT1,LIFR-AS1,LINC00338,LINC00511,MIAT,MLLT4-AS1,OIP5-AS1,RP11-145M9.4,RP11-216F19.2,RP11-220I1.1,RP11-227G15.3,RP11-280F2.2,RP11-290F20.1,RP11-303E16.8,RP11-311C24.1,RP11-347I19.3,RP11-373L24.1,RP11-429J17.2,RP11-467L20.9,RP11-480D4.3,RP11-615I2.7,RP11-618G20.1,RP11-690G19.3,RP4-665N4.8,RP5-837J1.2,SETD5-AS1,SIK3-IT1,SPPL2B,TUG1,U47924.19,XIST,ZNF518A,ZNF761	Onco-miR
hsa-mir-497-5p	AC003092.1,AC003104.1,AC004383.4,AC005154.5,AC005154.6,AC005537.2,AC005562.1,AC011893.3,AC016629.8,AC074093.1,AC084219.4,AC090587.2,AC091878.1,AC108142.1,AC113189.5,AP000721.4,AP001065.2,C14orf169,C1RL-AS1,CERS6-AS1,CTA-204B4.6,CTB-50E14.6,CTB-89H12.4,CTBP1-AS1,CTC-228N24.3,CTC-246B18.8,CTC-429P9.3,CTC-444N24.11,CTD-2201E18.3,CTD-2339L15.3,CTD-2516F10.2,CTD-2574D22.4,CWC15,DCP1A,DLG1-AS1,DLX6-AS1,EPB41L4A-AS1,ERI3-IT1,ERVK13-1,FENDRR,FGD5-AS1,GS1-124K5.11,GS1-358P8.4,HCG17,HCG18,IQCH-AS1,KIF9-AS1,LA16c306E5.2,LINC00094,LINC00176,LINC00339,LINC00473,LINC00511,LINC00649,LINC00662,LINC00707,LL22NC03-	Onco-miR


---

N27C7.1,MCM3AP-AS1,MEG8,MIR497HG,NUTM2A-AS1,PDXDC2P,PVT1,RASAL2-AS1,RP11-1103G16.1,RP11-125K10.4,RP11-155D18.12,RP11-159D12.9,RP11-169K16.9,RP11-16E12.2,RP11-18A3.4,RP11-204M4.2,RP11-216F19.2,RP11-218M22.1,RP11-21N3.1,RP11-244H3.1,RP11-244O19.1,RP11-277L2.2,RP11-27I1.2,RP11-282K24.3,RP11-2C24.4,RP11-329L6.1,RP11-361F15.2,RP11-379K17.11,RP11-383C5.4,RP11-383J24.5,RP11-384K6.6,RP11-38J22.6,RP11-390P2.4,RP11-403I13.4,RP11-43D2.6,RP11-453E17.1,RP11-461L13.3,RP11-464F9.1,RP11-467L20.9,RP11-474P12.5,RP11-477D19.2,RP11-506M13.3,RP11-540O11.1,RP11-543D5.2,RP11-549J18.1,RP11-54O7.1,RP11-588K22.2,RP11-60I3.5,RP11-64K12.2,RP11-66B24.4,RP11-677M14.3,RP11-690G19.3,RP11-697M17.1,RP11-773D16.1,RP11-869B15.1,RP11-91G21.2,RP11-923I11.1,RP11-96D1.10,RP11-973H7.2,RP11-983P16.4,RP1-283E3.8,RP1-310O13.12,RP13-507I23.1,RP3-341D10.4,RP3-486L4.3,RP4-614O4.11,RP4-773N10.5,RP5-1028K7.2,RP5-1148A21.3,RP5-1172N10.3,RP5-1180C10.2,RP5-955M13.3,RP6-206I17.2,RP6-24A23.7,SCGB1B2P,SEMA3B,SENP3-EIF4A1,SLC37A4,SNHG1,SNHG12,SNHG16,SPPL2B,TRAF3IP2-AS1,TTN-AS1,XIST,XXbac-B461K10.4,XXbac-BPG32J3.20,YLPM1,ZNF518A,ZNRD1-AS1

250

### 251 3.7. miRNA-miRNA interaction

252 Here, it is predicted shown that microRNA are acting as ceRNA for each other's (Figure 8).




253

254 Figure 8: miRNA-miRNA, PmmR, regulatory interactions with 10 nodes and 19 edges. Here, all  
255 the input microRNAs are supposed to be therapeutically tumor suppressor. However, these  
256 microRNAs acts as a sponge to each other. Consequently, it is putative that this kind of  
257 interaction results in an oncogenic impact.

258 It results in enhancing microRNA regulatory role as tumor suppressor (Fig.7). Seven  
259 miRs show ceRNAs activity.miR-214 acts as sponge for (miR-125a, miR-99a, miR-139, miR-  
260 125b).miR -125a acts as sponge for miR-99a.miR- 99a acts as sponge for let -7c.miR-130a acts  
261 as sponge for (let-7c, mir-99a ).miR 195 acts as sponge for (let-7c, miR-99a).miR-497 acts as  
262 sponge for (let-7c, miR-99a).


### 263 **3.8. microRNA-PPI interaction**

264 Six major biological processes in HCC were resultants (Figure 9). These BP are GO:0051726  
265 regulation of cell cycle, GO:0071158 positive regulation of cell cycle arrest, GO:1901991  
266 negative regulation of mitotic cell cycle phase transition, GO:0040008 regulation of growth,  
267 GO:0042981 regulation of the apoptotic process, GO:0043066: Negative regulation of the  
268 apoptotic process. As shown in table 3, GO:0051726 (regulation of cell cycle) BP has 30 genes  
269 as targets for ten down expressed miRNAs in HCC. Because activation of the cell cycle is one of  
270 the major hallmarks of liver cancer. Hence, suppressing the cell cycle by miRNAs results in  
271 considering that activity as miRNA tumor suppressor. On the other hand, GO:0071158 (positive  
272 regulation of cell cycle arrest), GO:1901991 (negative regulation of mitotic cell cycle phase  
273 transition), GO:0042981 (regulation of apoptotic process) BPs have 7, 15, 27 genes,  
274 respectively, which are non-incorporated in HCC. It is because GO:0071158, GO:1901991, and  
275 GO:0042981 BPs are not hallmarks of causing liver cancer. Therefore, suppression of  
276 GO:0071158 by miRNAs results in oncogenic aspects.




GO:0051726 regulation of cell cycle






**GO:0071158 positive regulation of cell cycle arrest**






280

GO:1901991 negative regulation of mitotic cell cycle phase transition



281

GO:0042981 regulation of apoptotic process



282

GO:0040008 regulation of growth

283 Figure 9 shows biological processes retrieved from PPI network of 180 overexpressed genes and  
 284 572 down expressed genes in HCC.PPI network was analyzed by STRING.

285 **Table 3:** Illustration of the Biological process of PPI network and their matched microRNAs

Biological Process	microRNAs	Gene Target	Therapeutic effect of microRNA-PPI on HCC.
GO:0051726 regulation of cell cycle	hsa-mir-30a-5p hsa-mir-130a-3p hsa-miR-30e-5p hsa-mir-497-5p sa-mir-122-5p hsa-mir-223 hsa-let-7c hsa-mir-215	CDC7, DTL, PCNA RACGAP1 CDC7 BIRC5, CDK1, RACGAP1 BIRC5 CDK2,ECT2,E2F8,E2F8,E2F8,PLCB1 CKS2 CDC7,CDKN2A,DTL,E2F8,ECT2,FEN1,GPSM2	Tumor supressor
GO:0071158 positive regulation of cell cycle arrest	hsa-mir-195-5p hsa-mir-125b-5p	KIF14,MAD2L1,PSRC1,RACGAP1 BIRC5,CDK1 CDKN2A	Onco-miR
GO:1901991 negative regulation of mitotic cell cycle phase transition		AURKA,BIRC5,BLM,BUB1,BUB1B,CCNB1,CENPF,E2F8,EZH2,GTSE1,MAD2L1,PCNA,SFN,TRIP13,TTK	Onco-miR
GO:0040008 regulation of growth		ACSL4,CCNB1,CCNB2,CDKN2A,CDKN2C,FOXM1,G6PD,GPC3,KIF14,NDRG3,PLCB1,PSRC1,SFN,SMARCA4,SPP1,TKT	Tumor supressor
GO:0042981 regulation of apoptotic process		AKR1C3,ASNS,AURKA,BARD1,BIRC5,CDKN2A,DLG5,ECT2,G6PD,HMGB2,ID1,IRAK1,ITGA6,KIF14,MAD2L1,MDK,MELK,MMP9,NME1,NQO1,PEA15,ROBO1,SFN,SORT1,STIL, TOP2A,TP53I3	Onco-miR

GO:0043066:

Negative regulation of apoptotic process

of hsa-mir-145-5p  
hsa-mir-122-5p  
hsa-mir-375


ACAA2,ANGPTL4,ATF5,AXL,C8orf4,CAT,CC  
L19,CCL2,CCL21,CCL5,CNTFR,CTH,CXCL12,  
CYR61,DOCK8,DUSP1,EDNRB,FABP1,FAM13  
4B,FGA,FGB,FGFR2,FGG,FHL2,HAND2,HCLS  
1,HGF,HHIP,ID1,IGF1,IL7R,NAT8,NGFR,NTF3  
,PDK4,PKHD1,PLAC8,PPARGC1A,PTGS2,RG  
N,SERPINB9,SERPINE1,SOCS2,SPRY2,TEK,T  
HBS1,VNN1  
SERPINE1  
AXL, FHL2  
AXL

Tumor suppressor

286


### 287 3.9. Free survival analysis

288 Here, survival analysis shows us that ectopic expression of ( CCNB1, AURKA, BIRC5,  
289 HGF, IGF1, TOP2A) has poor survival progression in the long term in LIHC( Figure 10). It  
290 means that microRNA acting on these genes is non-additive value for curing HCC in the long  
291 term.




292 1.


293



294  
295



296  
297



298  
299

Figure 10: list of survival figures of the gene target.

300 **4. Discussion**

301 MicroRNAs are a promising therapeutic gene therapy for Cancer (Table 4).

302 **Table 4:** list of miRNAs as HCC therapy.

MicroRNA	Target	Pathway	Suppression or Activation activity of miRNA
miR-142	TGF-Beta	mTOR	Suppression
miR-199b-5p	TGF-Beta 1		
mir-139-5p	PDK1		
miR-223	Rab1		
miR-195	AEG-1	Wnt signaling	Suppression
miR-214-3p	PIM-1	JAK-STAT	Suppression

mIR-200	Pin1		
miR-199a-5p	MAP4K3		
miR-143	GATA6	MAPK cascade	Suppression
miR-125A	MMP11,SIRT7		
miR-200a	GAB1		

303  
304 They are involved in regulating many biological processes. Their ability to bind with 3' un-  
305 translated region of mRNAs recruit many factors to degrade mRNAs , consequently acting as a  
306 repressor for oncoprotein synthesis [48, 49] . It results in knocking down the pathologically  
307 causative genes of Cancer [50] (Table 3). However, they have putatively mysterious functions of  
308 acting through inversely dual role either as a tumor suppressor or oncomiR. Through our current  
309 work, we tried to uncover the dual role of a set of microRNAs in HCC. MicroRNAs, on the  
310 contrary to siRNAs, lack specificity to bind mRNAs, where MicroRNAs have binding seed  
311 regions with a high capacity to target multiple genes [51]. It is considered a drawback in  
312 microRNAs as an approach to gene therapy. It is experimentally invalid to target specific  
313 oncogenes to be knocked down by microRNA where microRNAs target tumor suppressor genes,  
314 off-targets, that result in activating cancerous biological processes. To uncover these dually  
315 mysterious microRNA functions, we have collected the common down- expressed genes of  
316 miRNAs HCC within different GEO and TCGA-LIHC databases. The chosen databases are for  
317 (HCC vs. cirrhotic non-cancer) and (G2/M phase of the cell cycle in vs. normal tissues) to cover  
318 different pathological stages of HCC.

319 Additionally, these datasets cover broad samples (446 HCC vs. 146 normal specimens).In this  
320 respect, we targeted only the microRNAs common in all the chosen datasets due to the  
321 inconsistency of the results as miRNA measurement technology is immature compared to gene  
322 expression's system where CapitalBio's is the least reliable dataset. Milteny's and TCGA's  
323 datasets generated the most consistent results. Affymetrix's arrays are weak in detecting the  
324 expression difference. Hence, we decided to integrate these datasets to get the common down-  
325 expressed miRNAs to ensure accuracy.


326 Our work aims to support the combinatorial therapy of microRNA. One technique activates  
327 the tumor suppressor genes, off-target genes, via designing a cassette of miRNA-guide RNA-  
328 CRISPR/Cas9 [52]. Maybe CRISPRa is a choice to be combined with microRNA to activate

329 these off-targets genes knocked down by microRNAs. An additional suggestion is to combine  
330 microRNA with an exogenous expression vector carrying the tumor suppressor genes. Also,  
331 combined tumor suppressor microRNA with those microRNAs that activate tumor suppressor  
332 genes via binding its 5'UTR is a third way to solve the drawback of microRNAs' dual role [53].  
333 The idea behind our suggested combinatorial therapy is that it helps most in increasing the level  
334 of expressed tumor suppressor genes within the cells.

335 Moreover; microRNA cocktail therapy should not be a combination of microRNAs which act as  
336 CeRNA for each other [54]. One example of the dual role of microRNAs is "how microRNAs  
337 regulate dually in colorectal cancer?"; It was reported that miRNAs show dual regulatory roles in  
338 colorectal Cancer [55]. In a wet lab, much microRNAs act dually. miR-375 shows dual  
339 functions in prostate cancer [56]. In Breast cancer, miR-181a acts as an onco-miR via targeting  
340 Bax, increasing metastasis. On the other hand, it acts as a tumor suppressor via targeting BCL-  
341 increasing apoptosis [57].



342 The final regulatory role of microRNA is evaluated by miRNA-LncRNA-mRNA-TFs  
 343 Crosstalk as an accumulative impact on how microRNA acts (Figure 11).



344  
 345 Figure 11: Regulatory role of microRNA as either oncomiR and/ or tumor suppressor miR.

346 LncRNA is 200 nt, acting as epigenetic regulators and as competing RNA for microRNA.  
 347 It results in decreasing in the affinity of microRNA to be available for mRNA. Subsequently, it is  
 348 predicted to alter microRNA regulatory role shifting it to be oncomiR for down expressed  
 349 miRNAs in Cancer. On the other hand, transcription factors act via either activator or suppressor

350 for the genes. So, microRNA acting on TFs results in either enhancing its tumor suppressor  
351 activity or shifting into being oncomiR. It is based on the ontology of the gene where TF targets.

352 Through our work, we concluded that microRNAs are incorporated in most hallmarks of  
353 hepatocellular carcinoma. However, these microRNAs' dual activity made the consideration of  
354 the dominance of one of both functions a tough decision. Hence, we strongly suggest that more  
355 investigations on the factors that affect which microRNA function types will predominate should  
356 be carried out to solve their Myth. We suggest enhancing the protocols of using microRNAs as a  
357 gene therapy by combing activating techniques with miRs. These activating techniques are to  
358 induce the tumor suppressor genes targeted by microRNAs.

### 359 **Conflict of Interest**

360 The authors declare that there are no conflicts of interest regarding the publication of this paper.

### 361 **Authors' Contributions**

362 Mahmoud M. Tolba, Bangli Soliman and Mahmoud Elhefnawi designed this project. Mahmoud  
363 M. Tolba and HebaT'Allah Nasser conducted the reseach. Mahmoud M. Tolba, Abdul Jabbar  
364 edited the manuscript.Mahmoud M.tolba designed the figures.

365

### 366 **References**

- 367 1. A. Roberti, A. F. Valdes, R. Torrecillas, M. F. Fraga and A. F. J. C. e. Fernandez, "Epigenetics  
368 in cancer therapy and nanomedicine," vol. 11, no. 1, pp. 1-18, 2019.
- 369 2. S. Heerboth, K. Lapinska, N. Snyder, M. Leary, S. Rollinson and S. Sarkar, "Use of epigenetic  
370 drugs in disease: an overview. Genet Epigenet. 2014; 6: 9–19," Ed.
- 371 3. J. O'Brien, H. Hayder and Y. Zayed, "Overview of microRNA biogenesis, mechanisms of  
372 actions, and circulation, Front. Endocrinol., 2018, vol. 9, no. 402," Ed., 2018.
- 373 4. A. Wittrup and J. J. N. R. G. Lieberman, "Knocking down disease: a progress report on siRNA  
374 therapeutics," vol. 16, no. 9, pp. 543-552, 2015.
- 375 5. R.-W. Yao, Y. Wang and L.-L. J. N. c. b. Chen, "Cellular functions of long noncoding RNAs,"  
376 vol. 21, no. 5, pp. 542-551, 2019.
- 377 6. Y. A. Fouad and C. J. A. j. o. c. r. Aanei, "Revisiting the hallmarks of cancer," vol. 7, no. 5,  
378 pp. 1016, 2017.
- 379 7. N. M. Tunissiolli, M. M. U. Castanhole-Nunes, P. M. Biselli-Chicote, É. C. Pavarino and R. F.  
380 J. A. P. j. o. c. p. A. da Silva, "Hepatocellular carcinoma: a comprehensive review of biomarkers,  
381 clinical aspects, and therapy," vol. 18, no. 4, pp. 863, 2017.

- 382 8. T. El Jabbour, S. M. Lagana and H. J. W. j. o. g. Lee, "Update on hepatocellular carcinoma:  
383 Pathologists' review," vol. 25, no. 14, pp. 1653, 2019.
- 384 9. P. Golabi, S. Fazel, M. Otgonsuren, M. Sayiner, C. T. Locklear and Z. M. J. M. Younossi,  
385 "Mortality assessment of patients with hepatocellular carcinoma according to underlying disease  
386 and treatment modalities," vol. 96, no. 9, 2017.
- 387 10. L. P. Waller, V. Deshpande and N. J. W. j. o. h. Pyrsopoulos, "Hepatocellular carcinoma: A  
388 comprehensive review," vol. 7, no. 26, pp. 2648, 2015.
- 389 11. D. Dimitroulis, C. Damaskos, S. Valsami, S. Davakis, N. Garmpis, E. Spartalis, A.  
390 Athanasiou, D. Moris, S. Sakellariou and S. J. W. j. o. g. Kykalos, "From diagnosis to treatment  
391 of hepatocellular carcinoma: An epidemic problem for both developed and developing world,"  
392 vol. 23, no. 29, pp. 5282, 2017.
- 393 12. F. Vasuri, M. Visani, G. Acquaviva, T. Brand, M. Fiorentino, A. Pession, G. Tallini, A.  
394 D'Errico and D. J. W. j. o. g. de Biase, "Role of microRNAs in the main molecular pathways of  
395 hepatocellular carcinoma," vol. 24, no. 25, pp. 2647, 2018.
- 396 13. R. C. Lee, R. L. Feinbaum and V. J. c. Ambros, "The *C. elegans* heterochronic gene *lin-4*  
397 encodes small RNAs with antisense complementarity to *lin-14*," vol. 75, no. 5, pp. 843-854,  
398 1993.
- 399 14. H. Ling, M. Fabbri and G. A. J. N. r. D. d. Calin, "MicroRNAs and other non-coding RNAs  
400 as targets for anticancer drug development," vol. 12, no. 11, pp. 847-865, 2013.
- 401 15. K. Felekis, E. Touvana, C. Stefanou and C. J. H. Deltas, "microRNAs: a newly described  
402 class of encoded molecules that play a role in health and disease," vol. 14, no. 4, pp. 236, 2010.
- 403 16. F. Zhang and D. J. G. Wang, "The pattern of microRNA binding site distribution," vol. 8, no.  
404 11, pp. 296, 2017.
- 405 17. K. C. Miranda, T. Huynh, Y. Tay, Y.-S. Ang, W.-L. Tam, A. M. Thomson, B. Lim and I. J.  
406 C. Rigoutsos, "A pattern-based method for the identification of MicroRNA binding sites and  
407 their corresponding heteroduplexes," vol. 126, no. 6, pp. 1203-1217, 2006.
- 408 18. M. M. Chong, G. Zhang, S. Cheloufi, T. A. Neubert, G. J. Hannon, D. R. J. G. Littman and  
409 development, "Canonical and alternate functions of the microRNA biogenesis machinery," vol.  
410 24, no. 17, pp. 1951-1960, 2010.
- 411 19. L.-A. MacFarlane and P. J. C. g. R. Murphy, "MicroRNA: biogenesis, function and role in  
412 cancer," vol. 11, no. 7, pp. 537-561, 2010.
- 413 20. J. O'Brien, H. Hayder, Y. Zayed and C. J. F. i. e. Peng, "Overview of microRNA biogenesis,  
414 mechanisms of actions, and circulation," vol. 9, pp. 402, 2018.
- 415 21. J. Krol, I. Loedige and W. J. N. R. G. Filipowicz, "The widespread regulation of microRNA  
416 biogenesis, function and decay," vol. 11, no. 9, pp. 597-610, 2010.
- 417 22. G. J. Gordon, *Bioinformatics in cancer and cancer therapy*, Springer Science & Business  
418 Media, 2008.
- 419 23. Á. L. Riffo-Campos, I. Riquelme and P. J. I. j. o. m. s. Brebi-Mieville, "Tools for sequence-  
420 based miRNA target prediction: what to choose?," vol. 17, no. 12, pp. 1987, 2016.
- 421 24. P. Loher and I. J. B. Rigoutsos, "Interactive exploration of RNA22 microRNA target  
422 predictions," vol. 28, no. 24, pp. 3322-3323, 2012.
- 423 25. I. S. Vlachos and A. G. Hatzigeorgiou, "Functional analysis of miRNAs using the DIANA  
424 tools online suite," in *Drug Target miRNA*, Ed., pp. 25-50, Springer, 2017.
- 425 26. D. Betel, A. Koppal, P. Agius, C. Sander and C. J. G. b. Leslie, "Comprehensive modeling of  
426 microRNA targets predicts functional non-conserved and non-canonical sites," vol. 11, no. 8, pp.  
427 1-14, 2010.

- 428 27. J. Jarroux, A. Morillon and M. J. L. N. C. R. B. Pinskaya, "History, discovery, and  
429 classification of lncRNAs," pp. 1-46, 2017.
- 430 28. T. Mitsis, A. Efthimiadou, F. Bacopoulou, D. Vlachakis, G. P. Chrousos and E. J. W. A. o. S.  
431 J. Eliopoulos, "Transcription factors and evolution: an integral part of gene expression," vol. 2,  
432 no. 1, pp. 3-8, 2020.
- 433 29. S. A. J. B. Teichmann, "Principles of protein-protein interactions," vol. 18, no. suppl\_2, pp.  
434 S249-S249, 2002.
- 435 30. J. B. Berletch, F. Yang and C. M. J. G. b. Distche, "Escape from X inactivation in mice and  
436 humans," vol. 11, no. 6, pp. 1-7, 2010.
- 437 31. E. Clough and T. Barrett, "The gene expression omnibus database," in *Statistical genomics*,  
438 Ed., pp. 93-110, Springer, 2016.
- 439 32. Barrett T. Gene Expression Omnibus (GEO) 2013 May 19. In: The NCBI Handbook  
440 [Internet]. 2nd edition. Bethesda (MD): National Center for Biotechnology Information (US);  
441 2013-. "<https://www.ncbi.nlm.nih.gov/books/NBK159736/>."
- 442 33. A. Ruepp, A. Kowarsch, D. Schmidl, F. Buggenthin, B. Brauner, I. Dunger, G. Fobo, G.  
443 Frishman, C. Montrone and F. J. J. G. b. Theis, "PhenomiR: a knowledgebase for microRNA  
444 expression in diseases and biological processes," vol. 11, no. 1, pp. 1-11, 2010.
- 445 34. S. Griffiths-Jones, H. K. Saini, S. Van Dongen and A. J. J. N. a. r. Enright, "miRBase: tools  
446 for microRNA genomics," vol. 36, no. suppl\_1, pp. D154-D158, 2007.
- 447 35. A. Kozomara and S. J. N. a. r. Griffiths-Jones, "miRBase: integrating microRNA annotation  
448 and deep-sequencing data," vol. 39, no. suppl\_1, pp. D152-D157, 2010.
- 449 36. H. Dweep, C. Sticht, P. Pandey and N. J. J. o. b. i. Gretz, "miRWalk–database: prediction of  
450 possible miRNA binding sites by “walking” the genes of three genomes," vol. 44, no. 5, pp. 839-  
451 847, 2011.
- 452 37. J. Krüger and M. J. N. a. r. Rehmsmeier, "RNAhybrid: microRNA target prediction easy, fast  
453 and flexible," vol. 34, no. suppl\_2, pp. W451-W454, 2006.
- 454 38. B. Fromm, T. Billipp, L. E. Peck, M. Johansen, J. E. Tarver, B. L. King, J. M. Newcomb, L.  
455 F. Sempere, K. Flatmark and E. J. A. r. o. g. Hovig, "A uniform system for the annotation of  
456 vertebrate microRNA genes and the evolution of the human microRNAome," vol. 49, pp. 213-  
457 242, 2015.
- 458 39. I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I.  
459 Kanellos, I.-L. Anastasopoulos, S. Maniou, K. Karathanou and D. J. N. a. r. Kalfakakou,  
460 "DIANA-TarBase v7. 0: indexing more than half a million experimentally supported miRNA:  
461 mRNA interactions," vol. 43, no. D1, pp. D153-D159, 2015.
- 462 40. H.-Y. Huang, Y.-C.-D. Lin, J. Li, K.-Y. Huang, S. Shrestha, H.-C. Hong, Y. Tang, Y.-G.  
463 Chen, C.-N. Jin and Y. J. N. a. r. Yu, "miRTarBase 2020: updates to the experimentally validated  
464 microRNA–target interaction database," vol. 48, no. D1, pp. D148-D154, 2020.
- 465 41. B. T. Sherman and R. A. J. N. p. Lempicki, "Systematic and integrative analysis of large  
466 gene lists using DAVID bioinformatics resources," vol. 4, no. 1, pp. 44, 2009.
- 467 42. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B.  
468 Schwikowski and T. J. G. r. Ideker, "Cytoscape: a software environment for integrated models of  
469 biomolecular interaction networks," vol. 13, no. 11, pp. 2498-2504, 2003.
- 470 43. Y. Fan, K. Siklenka, S. K. Arora, P. Ribeiro, S. Kimmins and J. J. N. a. r. Xia, "miRNet-  
471 dissecting miRNA-target interactions and functional associations through network-based visual  
472 analysis," vol. 44, no. W1, pp. W135-W141, 2016.

- 473 44. M. Hamed, C. Spaniol, M. Nazarieh and V. J. N. a. r. Helms, "TFmiR: a web server for  
474 constructing and analyzing disease-specific transcription factor and miRNA co-regulatory  
475 networks," vol. 43, no. W1, pp. W283-W288, 2015.
- 476 45. D. Sengupta and S. J. M. B. Bandyopadhyay, "Participation of microRNAs in human  
477 interactome: extraction of microRNA–microRNA regulations," vol. 7, no. 6, pp. 1966-1973,  
478 2011.
- 479 46. D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M.  
480 Simonovic, A. Roth, A. Santos and K. P. J. N. a. r. Tsafou, "STRING v10: protein–protein  
481 interaction networks, integrated over the tree of life," vol. 43, no. D1, pp. D447-D452, 2015.
- 482 47. Z. Tang, C. Li, B. Kang, G. Gao, C. Li and Z. J. N. a. r. Zhang, "GEPIA: a web server for  
483 cancer and normal gene expression profiling and interactive analyses," vol. 45, no. W1, pp.  
484 W98-W102, 2017.
- 485 48. C. M. Ferreira, I. S. Pinto, E. V. Soares and H. M. J. R. A. Soares, "(Un) suitability of the use  
486 of pH buffers in biological, biochemical and environmental studies and their interaction with  
487 metal ions—a review," vol. 5, no. 39, pp. 30989-31003, 2015.
- 488 49. W. Ji, B. Sun and C. J. G. Su, "Targeting microRNAs in cancer gene therapy," vol. 8, no. 1,  
489 pp. 21, 2017.
- 490 50. X. Xu, Y. Tao, L. Shan, R. Chen, H. Jiang, Z. Qian, F. Cai, L. Ma and Y. J. J. o. C. Yu, "The  
491 role of MicroRNAs in hepatocellular carcinoma," vol. 9, no. 19, pp. 3557, 2018.
- 492 51. T. Ahmadzada, G. Reid and D. R. J. B. r. McKenzie, "Fundamentals of siRNA and miRNA  
493 therapeutics and a review of targeted nanoparticle delivery systems in breast cancer," vol. 10, no.  
494 1, pp. 69-86, 2018.
- 495 52. H. A. Seo, S. Moeng, S. Sim, H. J. Kuh, S. Y. Choi and J. K. J. C. Park, "MicroRNA-based  
496 combinatorial cancer therapy: effects of MicroRNAs on the efficacy of anti-cancer therapies,"  
497 vol. 9, no. 1, pp. 29, 2020.
- 498 53. I. Lee, S. S. Ajay, J. I. Yook, H. S. Kim, S. H. Hong, N. H. Kim, S. M. Dhanasekaran, A. M.  
499 Chinnaiyan and B. D. J. G. r. Athey, "New class of microRNA targets containing simultaneous  
500 5'-UTR and 3'-UTR interaction sites," vol. 19, no. 7, pp. 1175-1183, 2009.
- 501 54. X. Qi, D.-H. Zhang, N. Wu, J.-H. Xiao, X. Wang and W. J. J. o. m. g. Ma, "ceRNA in  
502 cancer: possible functions and clinical implications," vol. 52, no. 10, pp. 710-718, 2015.
- 503 55. L. Ding, Z. Lan, X. Xiong, H. Ao, Y. Feng, H. Gu, M. Yu and Q. J. I. j. o. m. s. Cui, "The  
504 dual role of microRNAs in colorectal cancer progression," vol. 19, no. 9, pp. 2791, 2018.
- 505 56. P. Costa-Pinheiro, J. Ramalho-Carvalho, F. Q. Vieira, J. Torres-Ferreira, J. Oliveira, C. S.  
506 Gonçalves, B. M. Costa, R. Henrique and C. J. C. e. Jerónimo, "MicroRNA-375 plays a dual role  
507 in prostate carcinogenesis," vol. 7, no. 1, pp. 1-14, 2015.
- 508 57. C. Yang, S. N. Tabatabaei, X. Ruan, P. J. C. P. Hardy and Biochemistry, "The dual  
509 regulatory role of MiR-181a in breast cancer," vol. 44, no. 3, pp. 843-856, 2017.